Mineralys Therapeutics (MLYS) Treasury Shares (2022 - 2025)
Mineralys Therapeutics (MLYS) posted Treasury Shares of $125793.0 for Q4 2025, down 66.01% sequentially from $370106.0 in Q4 2024, and down 66.01% YoY from $370106.0 in Q4 2024.
Mineralys Therapeutics (MLYS) Treasury Shares (2022 - 2025) Analysis & Trends
Mineralys Therapeutics has reported Treasury Shares for 4 years, with the latest figure at $125793.0 in Q4 2025.
- Quarterly Treasury Shares fell 66.01% year-over-year to $125793.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $125793.0 (down 66.01% YoY) and the FY2025 annual result came in at $125793.0, down 66.01% from the prior year.
- Treasury Shares eased to $125793.0 in Q4 2025 per MLYS's latest filing, from $370106.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $136.5 million in Q2 2022 and troughed at $125793.0 in Q4 2025.
- A 4-year average of $60.1 million and a median of $43.7 million in 2022 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2023 and 2024: Treasury Shares slumped 98.83% in 2023, then plunged 63.28% in 2024.
- Over 4 years, Treasury Shares stood at $86.3 million in 2022, then plunged by 98.83% to $1.0 million in 2023, then slumped by 63.28% to $370106.0 in 2024, then sank by 66.01% to $125793.0 in 2025.
- According to Business Quant data, Treasury Shares over the past three periods registered $125793.0, $370106.0, and $1.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 125,793.00 |
| Dec 31, 2025 | 125,793.00 |
| Dec 31, 2024 | 370,106.00 |
| Dec 31, 2024 | 370,106.00 |
| Dec 31, 2023 | 1.01 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Dec 31, 2022 | 86.33 Mn |
| Dec 31, 2022 | 86.33 Mn |
| Sep 30, 2022 | 136.51 Mn |
| Sep 30, 2022 | 136.51 Mn |
| Jun 30, 2022 | 136.51 Mn |
| Jun 30, 2022 | 136.51 Mn |